Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025
Ascendis Pharma shares fell 4.2% to around $197.25 in late trading December 9 after a Q3 earnings miss and a three-month FDA review delay for its key dwarfism drug. Volume was about 76% below average. The company posted Q3 revenue of €213.6 million but reported a net loss of €61 million, mainly from finance expenses. Despite the pullback, ASND remains near its 52-week high and up year-on-year.
